Jørgen Jensen

Expanding the upper age limit for cervical cancer screening: a protocol for a nationwide non-randomised intervention study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Expanding the upper age limit for cervical cancer screening : a protocol for a nationwide non-randomised intervention study. / Tranberg, Mette; Petersen, Lone Kjeld; Elfström, Klara Miriam; Hammer, Anne; Blaakær, Jan; Bennetsen, Mary Holten; Jensen, Jørgen Skov; Andersen, Berit.

I: BMJ Open, Bind 10, Nr. 11, e039636, 11.2020.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{b8c0e9b55dc2436ba3c2fb701dc33248,
title = "Expanding the upper age limit for cervical cancer screening: a protocol for a nationwide non-randomised intervention study",
abstract = "INTRODUCTION: Cervical cancer screening ceases between the ages of 60 and 65 in most countries. Yet, a relatively high proportion of cervical cancers are diagnosed in women above the screening age. This study will evaluate if screening of women aged 65-69 years may result in increased detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) compared with women not invited to screening. Invited women may choose between general practitioner (GP)-based screening or cervico-vaginal self-sampling. Furthermore, the study will assess if self-sampling is superior to GP-based screening in reaching long-term unscreened women. METHODS AND ANALYSIS: This population-based non-randomised intervention study will include 10 000 women aged 65-69 years, with no record of a cervical cytology sample or screening invitation in the 5 years before inclusion. Women who have opted-out of the screening programme or have a record of hysterectomy or cervical amputation are excluded. Women residing in the Central Denmark Region (CDR) are allocated to the intervention group, while women residing in the remaining four Danish regions are allocated to the reference group. The intervention group is invited for human papillomavirus-based screening by attending routine screening at the GP or by requesting a self-sampling kit. The reference group receives standard care which is the opportunity to have a cervical cytology sample obtained at the GP or by a gynaecologist. The study started in April 2019 and will run over the next 4.5 years. The primary outcome will be the proportion of CIN2+ detected in the intervention and reference groups. In the intervention group, the proportion of long-term unscreened women attending GP-based screening or self-sampling will be compared. ETHICS AND DISSEMINATION: The study has been submitted to the Ethical Committee in the CDR which deemed that the study was not notifiable to the Committee and informed consent is therefore not required. The study is approved by the Danish Data Protection Regulation and the Danish Patient Safety Authority. Results will be disseminated in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04114968.",
keywords = "cytopathology, epidemiology, gynaecology, preventive medicine, public health, QUALITY, EFFICACY, GUIDELINES, ELDERLY-WOMEN, PATHOLOGY, DENMARK, HEALTH, TOOL",
author = "Mette Tranberg and Petersen, {Lone Kjeld} and Elfstr{\"o}m, {Klara Miriam} and Anne Hammer and Jan Blaak{\ae}r and Bennetsen, {Mary Holten} and Jensen, {J{\o}rgen Skov} and Berit Andersen",
year = "2020",
month = nov,
doi = "10.1136/bmjopen-2020-039636",
language = "English",
volume = "10",
journal = "B M J Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "11",

}

RIS

TY - JOUR

T1 - Expanding the upper age limit for cervical cancer screening

T2 - a protocol for a nationwide non-randomised intervention study

AU - Tranberg, Mette

AU - Petersen, Lone Kjeld

AU - Elfström, Klara Miriam

AU - Hammer, Anne

AU - Blaakær, Jan

AU - Bennetsen, Mary Holten

AU - Jensen, Jørgen Skov

AU - Andersen, Berit

PY - 2020/11

Y1 - 2020/11

N2 - INTRODUCTION: Cervical cancer screening ceases between the ages of 60 and 65 in most countries. Yet, a relatively high proportion of cervical cancers are diagnosed in women above the screening age. This study will evaluate if screening of women aged 65-69 years may result in increased detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) compared with women not invited to screening. Invited women may choose between general practitioner (GP)-based screening or cervico-vaginal self-sampling. Furthermore, the study will assess if self-sampling is superior to GP-based screening in reaching long-term unscreened women. METHODS AND ANALYSIS: This population-based non-randomised intervention study will include 10 000 women aged 65-69 years, with no record of a cervical cytology sample or screening invitation in the 5 years before inclusion. Women who have opted-out of the screening programme or have a record of hysterectomy or cervical amputation are excluded. Women residing in the Central Denmark Region (CDR) are allocated to the intervention group, while women residing in the remaining four Danish regions are allocated to the reference group. The intervention group is invited for human papillomavirus-based screening by attending routine screening at the GP or by requesting a self-sampling kit. The reference group receives standard care which is the opportunity to have a cervical cytology sample obtained at the GP or by a gynaecologist. The study started in April 2019 and will run over the next 4.5 years. The primary outcome will be the proportion of CIN2+ detected in the intervention and reference groups. In the intervention group, the proportion of long-term unscreened women attending GP-based screening or self-sampling will be compared. ETHICS AND DISSEMINATION: The study has been submitted to the Ethical Committee in the CDR which deemed that the study was not notifiable to the Committee and informed consent is therefore not required. The study is approved by the Danish Data Protection Regulation and the Danish Patient Safety Authority. Results will be disseminated in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04114968.

AB - INTRODUCTION: Cervical cancer screening ceases between the ages of 60 and 65 in most countries. Yet, a relatively high proportion of cervical cancers are diagnosed in women above the screening age. This study will evaluate if screening of women aged 65-69 years may result in increased detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) compared with women not invited to screening. Invited women may choose between general practitioner (GP)-based screening or cervico-vaginal self-sampling. Furthermore, the study will assess if self-sampling is superior to GP-based screening in reaching long-term unscreened women. METHODS AND ANALYSIS: This population-based non-randomised intervention study will include 10 000 women aged 65-69 years, with no record of a cervical cytology sample or screening invitation in the 5 years before inclusion. Women who have opted-out of the screening programme or have a record of hysterectomy or cervical amputation are excluded. Women residing in the Central Denmark Region (CDR) are allocated to the intervention group, while women residing in the remaining four Danish regions are allocated to the reference group. The intervention group is invited for human papillomavirus-based screening by attending routine screening at the GP or by requesting a self-sampling kit. The reference group receives standard care which is the opportunity to have a cervical cytology sample obtained at the GP or by a gynaecologist. The study started in April 2019 and will run over the next 4.5 years. The primary outcome will be the proportion of CIN2+ detected in the intervention and reference groups. In the intervention group, the proportion of long-term unscreened women attending GP-based screening or self-sampling will be compared. ETHICS AND DISSEMINATION: The study has been submitted to the Ethical Committee in the CDR which deemed that the study was not notifiable to the Committee and informed consent is therefore not required. The study is approved by the Danish Data Protection Regulation and the Danish Patient Safety Authority. Results will be disseminated in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT04114968.

KW - cytopathology

KW - epidemiology

KW - gynaecology

KW - preventive medicine

KW - public health

KW - QUALITY

KW - EFFICACY

KW - GUIDELINES

KW - ELDERLY-WOMEN

KW - PATHOLOGY

KW - DENMARK

KW - HEALTH

KW - TOOL

UR - http://www.scopus.com/inward/record.url?scp=85095743383&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2020-039636

DO - 10.1136/bmjopen-2020-039636

M3 - Journal article

C2 - 33154056

AN - SCOPUS:85095743383

VL - 10

JO - B M J Open

JF - B M J Open

SN - 2044-6055

IS - 11

M1 - e039636

ER -